Supplementary Figure 3

Sep 01, 2014

10 likes | 116 Vues

Supplementary Figure 3. a. b. BMDM. BMDM. c. d. BMDM. BMDM.

Share Presentation

Embed Code

Link

bmdm
supplementary figure 3

bryce

Télécharger la présentation

Supplementary Figure 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplementary Figure 3 a b BMDM BMDM c d BMDM BMDM

Supplementary Figure 3

Supplementary Figure 3. A. B. Dry weight of grain in a panicle (g/panicle) .

105 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. #. . . 2.0. #. . #. . 1.5. #. Luciferase Activity. 1.0. 0.5. 0.0. Vehicle IL-1α SC-514 [50 μ M]. +--. --+. -+-. -++. +--. --+. -+-. -++. +--. --+. -+-. -++. +--. --+. -+-. -++.

112 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. MDSC subsets. Lymphocyte subsets. Treg subsets.

104 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. A. B.

80 views • 1 slides

Supplementary Figure 3 6

A. B. C. Supplementary Figure 3 6.

92 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. Cell Lines. TOV112D. TOV21G. HEY. HES. T80. IE. 102 kDa. 76 kDa. Transferrin receptor (CD71). Ferritin (FTH). 17 kDa. 12 kDa. 76 kDa. p66 Shc. 52 kDa. p52 Shc. p46 Shc. 17 kDa. LC3-I. LC3-II. 12 kDa. 17 kDa. LC3-I. 12 kDa. LC3-II. 120 kDa.

115 views • 1 slides

Supplementary Figure 3

control. control. ZVAD. ZVAD. JNK Inhibitor. JNK Inhibitor. ZVAD+JNK Inhibitor. ZVAD+JNK Inhibitor. 120. 100. 80. % Control. 60. 40. 20. 0. 0. 6.25. 12.5. 25. 50. Cerulenin μ M. U266. 120. 100. 80. % Control. 60. 40. 20. 0. 0. 6.25. 12.5. 25. 50.

127 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. Telomeric aUPD. A. Total aUPD. B. MRC. MRC. MRC. MRC. MRC. GIST. GIST. GIST. GIST. GIST. EWS. EWS. EWS. EWS. EWS. aRMS. aRMS. aRMS. aRMS. aRMS. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. D. C.

135 views • 1 slides

Supplementary figure 3

1. 2. 3. 4. 5. 6. M. M. 1. 2. Probe: Unc5b. 7 kb. 28 s RNA. Supplementary figure 3. a. Specificity of the Unc5b splicing morpholino .

98 views • 1 slides

Supplementary Figure 3

A. Signal A= SE1 Photo No. = 1291. 3µm*. B. EHT = 10.00kV Zone Mag = 5.01KX WD = 14mm. Supplementary Figure 3.

90 views • 1 slides

Supplementary Figure 3

Ctl sip300. p300. E2F1. Actin. Cisp (24h). Supplementary Figure 3. A. B. 25. NT. Cisp (24h). 20. Apoptosis (%). 15. 10. 5. 0. Ctl. sip300. Neutralization of p300 prevents E2F1 accumulation and apoptosis in response to cisplatin.

128 views • 1 slides

Supplementary figure 3

Supplementary figure 3. A. B. C.

72 views • 1 slides

Supplementary Figure 3

4. A. dilutions vs OD450-NPPA. dilutions vs OD450-PP1A. dilutions vs OD450-PP2A. 3. 2. OD450nm. 1. 0. 2. 4. 8. 16. 32. 64. 128. 256. 512. 1024. 2048. Dilution factor (number x 1000). B. Competitors. NPP. PP1. PP2. Primary antibody. Coating antigens. NPP. 152. 302.

204 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3.

102 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. MDA-MB-231. MDA-MB-231 HM.

69 views • 1 slides

Supplementary Figure 3

t. t. OFF. ON. OFF. OFF. ON. ON. a1. a2. a3. a5. a6. a4. ON. OFF. b1. Firing rate (Hz). Seconds. Supplementary Figure 3. a. Dark background. (used in the fMRI experiments). Firing rate (Hz). Firing rate (Hz). Seconds. Seconds. Seconds. b. Isoluminant transition. OFF.

123 views • 2 slides

Supplementary Figure 3

b. a. d. c. Supplementary Figure 3.

78 views • 1 slides

Supplementary Figure 3

CNV Sensitivity Analysis Run 1. CNV Sensitivity Analysis Run 2. H460 (100%). H460 (100%). cMYC amplification. EGFR loss. H460 (50%). H460 (50%). H460 (25%). H460 (25%). H460 (12.5%). H460 (12.5%). H460 (6.25%). H460 (6.25%). Supplementary Figure 3.

98 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. PELP1 Tg. Con. A. Phos MAPK. Con. PELP1 Tg. B. Phos AKT. Figure S3. Representative IHC images showing the status of phos -MAPK ( A )and phos -AKT ( B )in the mammary glands of 6-month-old control and MMTV-rtTA-TetO-PELP1 bitransgenic mice.

225 views • 1 slides

Supplementary Figure 3

HCT116. HCT116-TP53KO. NT. 5FU. Ox. NT. 5FU. Ox. 5. 2. 4. LC3. 3. IC50 5FU (µM). 1. IC50 Oxaliplatin (µM). 2. 1. GAPDH. 0. 0. HCT116. HCT116 TP53KO. HCT116. HCT116 TP53KO. 6. 5. 4. 7. HCT116. IC50 5FU (µM). 3. 6. HCT116. 0.4. 2. 5. 4. 1. 0.3. IC50 5FU (µM).

146 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. a. iPrEC. Untreated. Untreated. Doxo (0,75 µM). DTX (10 nM). % ROS. % Apoptosis (Ann V+/PI- cells). b. iPrEC. -. -. -. -. -. -. +. +. +. +. +. +. c. NAC. NAC. EV. USP2a MUT. USP2a WT. Untreated. Untreated. Doxo (0,75 µM). Doxo

121 views • 1 slides

Supplementary Figure 3

Fold of difference. Fold of difference. FEMALES. A. BM. PB. *. *. *. *. B. Fold of difference. Fold of difference. MALES. BM. *. PB. *. *. Supplementary Figure 3. *p<0,05.

104 views • 1 slides

More Related